Ethinylestradiol/Levonorgestrel

10月20日，欧加隆旗下复方口服避孕药欣妈富隆（通用名：去氧孕烯炔雌醇片）正式在阿里健康大药房线上首发。作为国内目前唯一获批避孕和月经周期调控双适应症的复方短效口服避孕药，欣妈富隆上线互联网医药平台后，将全面提升用药可及性，助力女性获得包括避孕、月经健康、生育力保护在内的健康呵护。 复方口服避孕药（combined oral contraceptives，COC）是目前全球范围广泛使用的高效避孕方法之一，是含有低剂量雌激素和孕激素（与女性体内天然的雌激素和孕激素相似）的复合甾体激素制剂。正确使用 COC 不仅可以有效避孕，还可以调节月经。 数据显示，目前超过1/3的育龄期女性受到月经紊乱的困扰。一项纳入15个省市100个社区9951名女性的妇科常见病的随机抽样调查，结果显示，未绝经的女性中，月经紊乱女性占34.5%。 北京协和医院妇产科田秦杰教授指出，规律月经是女性生殖健康非常重要的信号，与生殖内分泌系统息息相关。月经周期规律性为相邻两次月经周期天数相差不超过7天，经期长度为7天以内，经期出血量为5-80mL可以称之为月经正常。现代社会女性的观念依然传统，并不认为月经失调是一种疾病，由于大多数女性对月经的认知不准确，即使发生了异常月经，也意识不到其潜在的问题，不会选择到医院寻求医生的帮助。 “尤其对于刚初潮后的青春期女性，尚不能形成比较规律的月经周期。其实，临床有很多种方式可以管理月经异常，比如在医生的指导下，服用短效口服避孕药调节月经周期也是一种方式，来提高学习、生活和工作质量。”田秦杰说。 资料显示，欣妈富隆（去氧孕烯炔雌醇片）是全球首个获批20μg炔雌醇的复方口服短效避孕药COC，在全球有超过40年的使用经验，也是继妈富隆（去氧孕烯炔雌醇片）后又一款低剂量炔雌醇(EE)产品，为女性提供更丰富的生殖健康守护和赋权自我的力量。 2022年，欣妈富隆正式回归中国市场，并于2023年7月正式进入国内医院。双通道政策下，今年5月，欣妈富隆正式进驻零售药店，10月正式在医药电商平台开售，实现了院内院外的全渠道便捷可及。 据了解，此次欧加隆联合阿里健康线上首发欣妈富隆，将借助阿里健康遍及全国百城的专业药品仓配体系与互联网诊疗能力，为更多中国女性提供专业有效、正品优质的创新治疗方案与药品服务。关爱女性多样化的健康需求，为女性管理自身特有健康需求提供便利。 一审| 黄佳 二审| 李芳晨 三审| 李静芝

Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. (“Insud”) a global pharmaceutical group based in Spain with a 45-year track record and a presence in over 50 countries. The former holders of Agile common stock voted to approve the acquisition at a special meeting of stockholders on August 22, 2024. Upon closing of the acquisition, former shareholders of Agile became entitled to receive $1.52 per share in cash, net of assumed liabilities and estimated transaction costs for an approximate total enterprise value of $45 million. Insud completed its acquisition of Agile through the merger of an indirect, wholly owned subsidiary of Insud with and into Agile, with Agile continuing as the surviving company and becoming an indirect subsidiary of Insud, pursuant to a definitive merger agreement dated as of June 25, 2024. With the completion of the transaction, Agile will no longer be listed on any public market. Advisors H.C. Wainwright & Co. acted as exclusive financial advisor to Agile Therapeutics, Inc. and Morgan, Lewis & Bockius LLP acted as its legal advisor. Loeb & Loeb LLP and RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc. About Agile Therapeutics, Inc.Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website and LinkedIn account. About Twirla®Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider Twirla’s reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m2. Twirla is also contraindicated in women over 35 years old who smoke. Cigarette smoking increases the risk of serious cardiovascular events from CHC use. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch. About Insud PharmaInsud Pharma is a pharmaceutical group with more than 45 years of history, presence in around 50 countries, 9,000 employees worldwide and 20 manufacturing plants. Insud Pharma operates throughout the value chain of the pharmaceutical industry, offering specialized knowledge in scientific research, development, manufacturing, sale and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and pharmaceutical products of brand for the care of humans and animals and biopharmaceuticals. Insud Pharma seeks to improve health throughout the world by providing accessible, effective, safe and quality pharmacological treatments through its different business units, with continuous investment in R&D and the latest technology. Forward Looking StatementsThis communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements concerning the Company’s plans, objectives, strategy and strategic objectives, future events, business conditions, results of operations, business outlook and other information may be forward looking statements. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including (i) the effect of the announcement or pendency of the merger on the Company’s business relationships, operating results and business generally, (ii) the risk that the merger disrupts the Company’s current plans and operations and potential difficulties in the Company’s employee retention as a result of the merger, (iii) the outcome of any legal proceedings that may be instituted against the Company related to the merger agreement or the merger, and (iv) the risk that the merger and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and to maintain relationships with customers, vendors, employees, stockholders and other business partners and on its operating results and business generally. The foregoing list of risk factors is not exhaustive. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, please refer to our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. The Company does not give any assurances that it will achieve its expectations. Contact: For Agile: Agile Therapeutics Investor Relationsir@agiletherapeutics.com For Insud: Communication DepartmentEdificio Ebrosa - Manuel Pombo Angulo, 28 3rd floor28050 Madrid, Spain.Tel: +34 91 771 15 00E-mail: comunicacion@insudpharma.com